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 Stroke and acute myocardial infarction is a disease with the highest mortality in the 
world. WHO has estimated in 2008, 30% of deaths from heart disease and more 
than 80% of this cases have been occurred in developing countries. Streptokinase 
(SK) as an effective thrombolytic agent has been used as a drug of choice for about 
forty years ago. SK is plasminogen (PG) activator that converts plasminogen to 
active protease, called plasmin (PN) which degrades fibrin to soluble products. 
Recombinant streptokinase (SKA) from genetic engineering has been developed at 
School of Pharmacy ITB to reduce or eliminate immunogenicity of SK. However, 
scientific disclosures relating to dynamic and its kinetic studies in the body have 
still to be proven. One method that can explain this phenomenon is the 
pharmacological studies using radionuclide labeled compounds. Radioiodine 
labeled compound is used extensively and most suitable for biological studies. This 
paper describes the preparation of 131I-SKA and its characterization. The labeling 
conditions of SKA, such as chloramine-T as an oxidizing agent, amount of SKA, 
incubation time, and size of resin to purify the labeling yield have been observed. 
The result showed that the optimum condition of labeling (35.11%) was obtained 
using 10 µg of chloramine-T and 60 seconds of incubation time. The highest 
radiochemical purity (97.46 ± 1.14%) has also been obtained by passing through the 
resin chromatography column using 100 mg Dowex 1x8, size 50-100 mesh. The 
characterization of 131I-SKA with SDS PAGE method and autoradiography showed 
the similar performance with unlabeled-SKA. 
 
© 2012 Atom Indonesia. All rights reserved
 
INTRODUCTION∗ 
 
Thrombosis is a condition of the blockage of 
blood vessel by fibrin clots that cause an acute 
myocardial infarction and stroke, and becoming 
leading of death [1]. In 2007, Ministry of Health 
stated that the highest rate of death has changed 
from infectious to degenerative diseases, and stroke 
has the leading causes of death [2]. The incidence of 
heart diseases has related to lifestyle changes [3]. 
Thrombolytic agents are the major options 
than surgery. It works as plasminogen (PG) 
activator by changing inert PG enzymatically in the 
fibrinolytic system becomes plasmin (PN) and 
dissolves the fibrin clot into soluble degradation 
products, and then degradation products will be 
phagocyte [1,4]. Several fibrinolytic drugs 
commonly used are streptokinase (SK), urokinase 
(UK), and tissue plasminogen activator (tPA) [4,5]. 
                                                
∗ Corresponding author. 
   E-mail address: isti@batan.go.id  
The drug selection is dependent on the price, side 
effect, severity, in vivo stability, specificity to 
fibrin, and immunological reactions. UK and tPA 
are immunological inert, but has a lower in-vivo 
stability and more expensive than SK that is 
naturally secreted from Streptococcus pyogenes 
M12 strain CS24 [5].   
Biotechnological research at School of 
Pharmacy ITB has developed several mutants of 
streptokinase (SKA) to obtain better in vivo activity 
which is associated with increasing of its biological 
half life and low immunological reaction. Based on 
the in-vitro experiments, the observation of 
pharmacological parameters and in vivo stability has 
to be explored [6]. Nuclear technique is a method of 
choice to observe this study. The advantages of this 
method are more sensitive, simple, and need only 
small sample to be analyzed.  The preparation of 
SKA labeled iodine-131 as a tracer to be used in this 
research has been investigated. There are many 
methods of protein labeling with radioiodine, mostly 
oxidative reaction. Iodine-131 have been proven to 
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be appropriated for labeling both small and large 
bio-molecules, protein or peptides, well known 
chemistry, availability easier, and low cost [7].  
 
 
EXPERIMENTAL METHODS 
 
The materials used were  Iodine-131 as Na131I 
solution (PT BATAN Technology), Bovine Serum 
Albumine (TCI), N,N,N’,N’-tetramethiletilene 
diamine (TEMED), coomassie blue R-250 
(Pharmacia), protein marker (Amersham), 
chloramine-T (Sigma), sodium metabisulfite 
(Merck), Whatman no. 1 paper, and DOWEX 1x8 
(Merck). The equipment used were protein 
electrophoresis (Bio-Rad), paper chromatography 
apparatus, dose calibrator (RI Deluxe Iisotop Calib 
II, Victoreen) and single channel analyzer 
(ORTEC). Streptokinase were obtained from Over-
production of Escherichia coli BL21 (DE3) consist 
of pET-32b ska. 
 
 
Animals 
 
Male Swiss mice with age of 3 months, and 
body weight of 40-45 g were used for 
pharmacokinetic study. Animals used in the 
experiments received care in compliance with the 
“Principles of Laboratory Animal Care” and “Guide 
for the Care and Use of Laboratory Animals” [8,9]. 
 
 
Over-production of SKA 
 
The SKA Over-production was performed on 
E.coli BL21 (DE3) containing pET-32b. Single 
colony of E.coli inoculated in 10 ml of liquid Luria 
Bertani broth containing 100µg/ml ampicillin as a 
selective medium. The culture was incubated for 
about 18h in a shaking incubator at 37oC, and then a 
total of 10 mL of medium inserted into 200 mL 
selective medium. Cultures were re-incubated for            
3 h at 37°C in a shaking incubator until OD600 
reached 0.3 to 0.4. Furthermore, the culture was 
induced with 0.5 mM IPTG and incubation was 
continued for an additional 3 hours, and then 
centrifugated at 4oC, 4500g for 15 min. Pellet cells 
obtained from sediment was re-suspended in 5 mL 
of lysis buffer (50 mM NaH2PO4 and 300 mM NaCl 
at pH 8.0) and PMSF to get a final concentration of 
1 mM, and lyzed by sonication at the amplitude of 
15 for 5 minutes. To prevent temperature elevation, 
the cells were sequentially sonicated and cooled on 
ice for several times, each time for 30s. Soluble 
protein were separated by centrifugation at 12,000 g, 
4°C for 15 min, and then purified using nickel 
affinity column according to the manufacturer’s 
protocol (Protino® Ni-Ted), and characterized by 
SDS-PAGE. Protein concentration was determined 
using Bradford method based on coomassie               
blue staining. 
 
 
Labeling optimization of SKA with               
Iodine-131 
 
SKA were labeled using radioiodine-131. The 
solution containing 6.2 µg of SKA in 50 µL PBS pH 
7.4 was added to the amount of chloramine-T (1 mg 
/ mL) which varied from 10-250µg. The solution 
was then shaked in a vortex mixer for 30 and 60 
seconds at room temperature. To stop the reaction 
immediately, the sodium metabisulfite solution with 
a concentration of 2 times the concentration of 
chloramine-T was added [10,11]. 
 
 
Purification of 131I-SKA 
 
Dowex 1x8 (Cl-) was first activated with 1 N 
HCl solution for 1 hour, then washed with water 
until neutral pH. Three different weights of Dowex 
(100, 500 and 1,500mg) was inserted into the 
column with a ± 1cm diameter, and rinsed with  
0.02 M phosphate buffer pH 7.5. The labeled            
131I-SKA was passed to the Dowex column and then 
eluted with 0.02 M phosphate buffer pH 7.5 
containing 1% BSA and 0.1% KI [10]. 0.5-mL of 
each fraction was collected and measured with a 
dose calibrator. The radiochemical purity was then 
determined by using chromatography system. 
 
 
Radiochemical purity determination                 
of 131I-SKA 
 
Radiochemical purity was determined by 
ascending paper chromatography method using 
stationary phase Whatman no. 1, and the mobile 
phase of methanol-water (85:15). Paper 
chromatogram was dried in oven at 80°C for 5 
minutes and then every 1 cm piece of paper is 
measured by the single-channel gamma counter 
detector NaI (Tl). Retention factor (Rf) of               
131I-SKA = 0.0 and Rf of iodide-131 = 0.6               
to 0.9 [12]. 
 
 
Characterization of 131I-SKA 
 
Characterization of 131I-SKA was determined 
using Sodium Polyacrylamide Gel Electrophoresis 
(SDS PAGE). A precisely 8 µL sample of 131I-SKA 
and 2 µL loading buffer inserted into the well 
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as the stationary phase, and a mixture of methanol : 
water (85 : 15) as the mobile phase [12]. Each 
component is characterized by an Rf value, which is 
defined as the ratio of the distance traveled by the 
component (131I-SKA and its impurities) to the 
distance the solvent advanced from the original 
point of application of the test material (Fig. 4).  
Radiochemical purity of 131I-SKA was calculated 
based on the count numbers of the peak area of              
131I-SKA (Rf = 0) divided by total counts of the                
peak area of 131I-SKA and the peak of impurities          
(Rf = 0.6 to 0.9) as follow: (Number of radioactive 
counts of 131I-SKA / Number of total activity)                
x 100% 
 
 
 
Fig. 4. Chromatogram of (a) 131I-SKA using Whatman no. 1 
(stationary phase) and methanol-water 85:15 (mobile phase) and 
(b) Na131I. 
 
A high labeling yield is always desirable, 
although it may not be attainable in many cases. 
Several parameters influenced were varied in order 
to get optimum condition in SKA labeling. The role 
of chloramine-T is very important in the 
radioiodination labeling; however, chloramine-T is a 
highly reactive substance and can cause 
denaturation of proteins [14]. The excess oxidizing 
agent can easily oxidise the molecule beeing 
labeled, and the addition of sodium metabisulfite 
can stop the reaction immediately. Table 1 showed 
the amount of SKA and chloramine-T used in the 
labeling. The highest labeling yield was obtained 
with molar ratio between chloramine-T : SKA = 1 : 
452 and 60s of incubation time.  
 
Table 1. Optimization of Chloramine T and incubation time  of 
131I-SKA labeling. 
 
 A B C D E F G 
SKA  (µg) 6.2 6.2 6.2 6.2 6.2 6.2 6.2 
Chloramine 
T (µg) 150 100 50 250 150 50 10 
Incubation 
time (s)  30 30 30 60 60 60 60 
Labeling 
Yield (%) 7.88 8.45 9.29 7.90 9.09 10.82 35.11 
Irrespective of the radio-labeling methods, the 
prepared product will require purification before 
use. To retain the enhanced sensitivity and precision 
of the biomedical studies, the purity of the label 
compound needs to be high. Radiochemical and 
chemical impurities arise from incomplete labeling 
of compounds and can be separated by various 
methods. For this reason, the 131I-SKA as a labeled 
product was immediately separated from impurities 
by ion exchange chromatography method. Dowex 
1x8 was selected resin that suitable for this purpose. 
Ion exchange was performed by passing the labeled 
product through a column ionic resin (Dowex 1x8) 
and eluting with phosphate buffer. The resin sizes 
and the diameters of the column were varied in 
order to obtain high radiochemical purity as shown 
in Table 2. The elution can be considerably 
improved by the presence of sufficient carrier 
protein (BSA) in the eluting buffer. The result 
showed that the optimum purification condition 
(97.7%) obtained by using 100mg Dowex 1x8, 50-
100 mesh and 0.5 cm diameter of column. 
 
Table 2. Optimization of purification 131I-SKA using              
DOWEX 1x8. 
Size 
colums 
(mesh) 
Resin 
(mg) 
Diameter 
(cm) 
Radiochemical purity 
(%) 
previous final 
100-200 500 1.5 9.29 - 
100-200 500 0.5 < 5 66.67 
50-100 1500 1.5 18.59 93.31 
50-100 100 0.5 18.95 97.70 
 
The purification profile of 131I-SKA, as shown 
in Fig. 5 and Table 3, illustrates the fraction number 
of elution. Radiochemical purity was decreased at 
the 3rd until the 5th fraction (<50%). The highest, 
both of radioactivity and radiochemical purity was 
found in the 2nd fraction.   
 
 
 
Fig. 5. Purification profile of 131I-SKA using Dowex 1x8,            
50-100 mesh, and 0.5cm of column diameter. 
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Table 3. Radioactivity of 131I-SKA fraction. 
Number of fraction Radioactivity 131I-SKA (mCi) 
1 0,005 
2 0,967 
3 0,055 
4 0,044 
5 0,039 
 
Sodium Dodecyl Sulphate Polyacrilamide Gel 
Electrophoresis (SDS PAGE) and autoradiography 
method has been used to characterize 131I-SKA 
labeled compound. Based on SDS PAGE analysis 
indicated that 131I-SKA bands parallel to unlabeled 
SKA with molecular weight of 63.8 kDa as also 
shown by autoradiography method in Fig. 6.               
This result proved that SKA has been labeled with 
iodine-131, and has not degraded during and after 
labeling.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6. Characterization of 131I-SKA SDS PAGE and  
autoradiography. 
 
In general, a labeled compound has a self               
life during which it can be used safely for                        
its intended purpose. The loss of efficacy of a 
labeled compound over a period of time may               
result from radiolysis and depends on the physical 
half life of the radionuclide, the nature of                 
emitted radiations, the solvent, any additive,                 
pH, and the nature of the chemical bond between                
the radionuclide and the molecule [10,14,15].                   
In this experiment, the stability of labeled 131I-SKA 
has been observed in various temperature, at               
25oC, 37oC, 4oC and -20oC. As shown on Fig. 7, 
131I-SKA was stable at 25oC and 37oC for                   
about 3 hours; however, the stability profile                      
at 37oC was lower than the product stored                 
at room temperature, it may be the increase                     
of temperature will affect the release of iodine                
atom from tyrosine chain of SKA [19].                          
The instability process was also shown by the 
decreasing of radiochemical purity after 3 days 
storage at 4oC and -20oC. On the second days,                
the radiochemical purity of SKA stored at -20oC 
(95.29%) still indicated better than 4oC (92.24%). 
131I-SKA can be stored for about 2 days at -20oC 
with radiochemical purity more than 95%. 
 
 
 
Fig. 7. Stability profile of 131I-SKA at (a) 25oC and (b) 37oC. 
 
 
 
Fig. 8. Stability profile of 131I-SKA at (a) -20°C and (b) 4°C. 
 
 
CONCLUSION 
 
The recombinant streptokinase (SKA)               
has been successfully labeled with radioiodine-131 
using the chloramine-T method. The labeling               
yield was about 35% with radiochemical               
purity more than 95%. The labeling yield               
was not very high, but the method allows               
iodination without alteration of SKA. The 
characteristics of 131I-SKA are suitable and can be 
used for biological studies such as in 
pharmacological trials using animal models               
or in other preclinical assessments. 
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